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Left ventricular non-compaction cardiomyopathy (LVNC) is a rare disease which belongs to
unclassified congenital cardiomyopathies. According to the ESC classification, LVNC is
characterized by a spongy appearance of myocardium due to increased trabeculation and
deep intertrabecular recesses that communicate with the left ventricle. This phenotype is
thought to be caused by arrest of normal endomyocardial morphogenesis. Clinical
manifestations of LVNC include heart failure, thromboembolic events, arrhythmias and/
or sudden cardiac death. Progression of LVNC is highly variable and prediction of prognosis
is very difficult. The aim of this paper is to provide an update about the topic of
isolated LVNC.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Left ventricular non-compaction cardiomyopathy (LVNC) is a
rare condition which, according to the European Society of
Cardiology classification, belongs to unclassified cardiomyo-
pathies with a genetic etiology [1]. Localized thickening of left
ventricular myocardium formed by thick spongiform myo-
cardium from the endocardial side and thin compact epicar-
dial layer is a typical feature of LVNC. Spongiform layer is
made up from densely trabeculated myocardium with typical
deep intertrabecular recesses communicating with the left
ventricular cavity [2,3]. The condition can be found as an
isolated disorder of myocardium (isolated LVNC) or may be
associated with congenital heart defects such as pulmonary
atresia, left or right ventricular outflow tract obstruction,
atrial or ventricular septal defect or Ebstein’s anomaly [2–4].
The aim of this review is to provide the summary of current
knowledge of the isolated form of LVNC.2. History
Non-compact myocardium was first described in 1932 when
Bellet et al. reported this anomaly in newborn with aortic
atresia and coronary artery-left ventricular fistula [1]. In 1975,
Czech authors Dusˇek et al. described first series of patients
with non-compact myocardium, some of whom would be
nowadays diagnosed with LVNC [5]. First clinical description
of LVNC diagnosed by echocardiography was published by
Engberding in 1984 [6]. The term isolated LVNC was proposed
by Chin et al. in 1990, who reported the first series of
clinically diagnosed cases [7]. Until then, this condition was
designated as spongious myocardium, myocardial dysplasia,
myocardial dysgenesis or persistence of myocardial sinusoids
[4]. In 1996, LVNC was included among unclassified cardio-
myopathies according to the WHO classification of cardio-
myopathies [8].3. Embryology
Most authors suppose that LVNC is determined by distur-
bance of embryogenesis [4] and its morphological features
result from increased trabeculation or arrest of myocardial
compaction. During the 4th week of human embryogenesis,
clonal proliferation of trabecules occurs and spongiform
myocardium develops [9]. In this period, myocardium is
formed by a meshwork of interwoven trabecules and cardi-
omyocytes are nourished by diffusion from circulating blood.
Within the 5th–8th week, the coronary bed develops and
during this process intertrabecular spaces for capillaries
form. Subsequently, progressive fusion of myocardial trabe-
cules occurs and compact myocardium prevails over the
sponge-like one. The formation of the compact layer happens
relatively fast within 10th–12th week and proceeds from left
ventricular basis to the apex, from epicardium towards
endocardium [9]. In accordance with the process of embry-
ogenesis, excessive trabecularization in LVNC is localized
usually in the apical area and adjacent segments of lateraland inferior wall of left ventricle. Sarcomere proteins
mutations—the most common cause of LVNC, may cause
excessive trabeculation or insufficient compaction of myo-
cardium and imbalance between these processes leads to
LVNC [10]. Sarcomere proteins mutations cause hypertrophic
and dilated cardiomyopathy as well, therefore it is not
surprising that these conditions can be diagnosed by screen-
ing in families with LVNC. Association of myocardial myosin
heavy chain mutations (MYH7) and myocardial actin muta-
tions (ACTC1) with non-compact myocardium, atrial and
ventricular septal defects has been confirmed. It seems that
correct sarcomere function is important for the accurate
septation of the heart. This explains why LVNC is associated
with congenital heart defects in some cases [10].4. Anatomical pathology, histology
Anatomical criteria for diagnosis of LVNC were defined by
Burke et al. [11]. Pathologicoanatomical diagnosis requires
two criteria to be fulfilled: (a) absence of normally formed
papillary muscles in left ventricle, (b) ratio of total left
ventricular wall thickness to compact myocardium greater
than 2. As far as right ventricle is concerned, at least 75% of
wall thickness must be formed by highly trabecularized
myocardium. Fig. 1(panel C) shows macroscopic finding of
the heart with LVNC, explanted by transplantation. Micro-
scopically, there is often endocardial thickening, endocardial
fibrosis or fibroelastosis, microinfarctions and foci of inter-
stitial fibrosis in LVNC [12]. In some cases, subendocardial
myocytes present perinuclear or extensive central vacuoliza-
tion which shows sublethal ischemic injury to myocytes,
caused by microvascular dysfunction in sponge-like myocar-
dial layer [13].5. Genetics
LVNC is a condition with prevailing familial incidence, spora-
dic form is less frequent. Careful cardiac screening showed
familial incidence in up to 63% of cases [14]. Genetic analyses
proved that the most common cause of LVNC is sarcomere
protein mutation. According to some studies, these are
detected in up to 29% of cases [15]. In general, the most
common mutation was MYH7, myosin- binding protein C
(MYBPC3), alpha tropomyosin (TMP1), myocardial actin
(ACTC1), troponin T (TNNT2) and myocardial troponin I
(TNNI3) [14–18]. Familial LVNC accompanied by occurrence
of hypertrophic, dilated and rarely restrictive cardiomyopathy
is typical for MYH7 mutation [17]. In ACTC1 mutation, apical
forms of hypertrophic cardiomyopathy were found in
families with LVNC [18]. Less common genetic disorders in
patients with LVNC include mutations of Z-band proteins
such as Cypher/ZASP protein [19], cytoskeleton proteins
mutations, i.e. alpha-dystrobrevin (DTNA) [20] or proteins
taking part in calcium transportation, i.e. calsequestrin
(CASQ2) and phospholamban (PLN) [14], nuclear membrane
proteins (lamin A/C) [21] or mitochondrial enzymes such as
protein G 4.5 belonging to tafazins [22] and some further
mutations [23]. These disorders are usually transmitted
Fig. 1 – Examples of characteristic findings in patient with LVNC. (Panel A): Echocardiographic image of non-compact
myocardium in apical and lateral part of left ventricular wall. Color Doppler flow mapping depicts the blood flow in
spongiform myocardium. (Panel B): Magnetic resonance (T1-weighted image with TrueFISP sequence) illustrating non-
compact myocardium in the four-chamber view. (Panel C): Macroscopic finding of the heart explanted by transplantation
(apical third of ventricles, Sikl’s technique). (Panel D): Magnetic resonance (T1-weighted image with TrueFISP sequence)
documenting the non-compact myocardium in the apical third of left ventricle (short axis view). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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penetrance. LVNC with G4.5 gene defect causing Barth syn-
drome in children is an exception, as it is gonosomally
transmitted. Dilated cardiomyopathy or LVNC at early age
in men, frequently accompanied by neutropenia, lactic acido-
sis and lipid metabolism abnormalities are typical for this
mutation [22]. Currently it is recommended to screen at least
three generations of families of patients with LVNC and to
perform cardiac evaluation in close relatives [24].6. Diagnostics
Echocardiography is a basic diagnostic tool for LVNC. Thicken-
ing of the left ventricular wall in the apical part below the
papillary muscles is typical for LVNC. It is formed by thick
sponge-like myocardial layer from the endocardial side withthin compact epicardial layer. Sponge-like layer is interwoven
with deep recesses communicating with the main cavity of the
left ventricle, this can be verified by color Doppler flowmapping
(Fig. 1panel A). In symptomatic individuals, these findings are
accompanied by left ventricular systolic or diastolic dysfunction
or by secondary atrioventricular regurgitations. Historically,
criteria stated by Chin et al. [7], Stollberger et al. [25] and Jenni
et al. [26] were applied for diagnostics of LVNC. According to
Chin, ratio of compact myocardial layer to total myocardial
thickness lower than 0.5 suggests LVNC. Echocardiographic
images should be assessed from parasternal and apical four-
chamber view at the end of diastole [7]. Stollberger’s criteria [25]
are rather qualitative. They are based on presence of three and
more trabecularizations entering the left ventricular cavity
visualized at single echocardiographic view. Further criterion
is the presence of deep intertrabecular recesses communicating
with left ventricular cavity on Doppler imaging. Jenni’s criteria
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and compact layer ratio is performed at the end of systole from
parasternal short axis view. Ratio of non-compact to compact
layer is considered to be diagnostic when greater than 2.0 in
adults and 1.4 in children. For the diagnosis of isolated LVNC,
presence of multiple trabecularizations in the apex and adja-
cent segments of lateral and inferior wall is required, as well as
proof of blood circulation between the intertrabecular recesses
and left ventricular cavity on Doppler flow imaging and absence
of other abnormalities [26]. Contrast echocardiography may
help in cases with poor standard echo visibility [27,28].
Presently, reliability of the stated diagnostic criteria is
controversial. Kohli et al. applied the above-mentioned cri-
teria to 199 patients with heart failure. Chin’s criteria were
fulfilled in 79%, Jenni’s criteria in 64% and Stollberger’s
criteria in 53% of cases. All criteria were met in only 30% of
cases. In the group of volunteers, at least one criterion for
LNVC was fulfilled in 14% of black patients and 3% of rest of
the patients [29]. It shows that current diagnostic criteria are
overly sensitive and may lead to overestimation of LVNC
prevalence. Quantification of non-compact myocardium by
3D echocardiography [30] or cardiac magnetic resonance
(CMRI) could offer a solution (Fig. 1panels B and D). Future
studies should include the patients with LVNC backed by
positive family history and positive genetic testing, respec-
tively. As mentioned, CMRI can be helpful due to 3 D-imaging
and better spatial resolution. In the work of Petersen et al.,
group of 7 patients with LVNC was compared to control
groups of healthy individuals, athletes, hypertensive patients,
patients with hypertrophic cardiomyopathy and aortic ste-
nosis. CMRI distinguished patients with LVNC with high
sensitivity and specificity (86% and 99%) [31]. The diagnostic
criterion for LVNC was the non-compact to compact myo-
cardium thickness ratio in diastole greater than 2.3. Jacquier
et al. used CMRI for quantitative evaluation of the spongiform
myocardial mass in LVNC. Volume of trabecularized mass
larger than 20% of total left ventricular mass distinguished
patients with LVNC with 94% sensitivity and specificity [32].
These results signalize that quantitative evaluation of the
non-compact mass could become a new standard for LVNC
diagnostics. The thickness of trabecularized and compact
layer of left ventricular wall were studied in large group of
healthy individuals by CMRI and normal values have been
established. From 4th decennium on, decrease in thickness of
trabecularized layer and increase in that of compact mass
has been described [33]. Other authors depicted relation
between delayed accumulation of gadolinium and severity
of heart failure in LVNC [34–36]. There is less information
concerning the use of computed tomography (CT) in LVNC
diagnostics. The asset of CT is a possibility of displaying the
coronary arteries and possible associated inborn anomalies
(i.e. pulmonary stenosis, patent ductus arteriosus)7. Epidemiology and natural course of LVNC
Prevalence of LVNC in retrospective studies lied between 4.5
and 26 in 10,000 individuals who had been sent for echocar-
diographic evaluation [37–39]. In the group of patients with
ejection fraction lower than 45%, LVNC was diagnosed in 3.7%[39]. In children, LVNC is the third most common cardiomyo-
pathy, representing approximately 9% of all cardiomyopa-
thies [40]. Clinical presentation is an important factor
concerning the analysis of incidence and prognosis. The
main clinical symptoms of LVNC are: signs of heart failure,
arrhythmias, chest pain and systemic embolizations [2,3].
First groups of patients included only severely symptomatic
patients in advanced stages with 58% rate of 5-year survival.
Sudden cardiac death, severe heart failure, systemic emboli-
zations or necessity of cardiac transplantation were frequent
[37–39,41]. Asymptomatic patients in initial phases of LVNC
were included into later studies, in accordance; 5-year prog-
nosis was more favorable with 75% rate of survival [42–44]. In
the work of Lofiego et al., advanced heart failure of NYHA III-
IV class, sustained ventricular tachycardias and left atrium
size were independent predictors of unfavorable prognosis
[43]. In the study of Habib et al., NYHA class III-IV, high filling
pressures of left ventricle, its ejection fraction and hospita-
lization due to heart failure were the predictive factors [44].
B-natriuretic peptide assessment can be applied for risk
stratification of LVNC [45].8. Clinical presentation and treatment
Clinical presentation of LVNC illustrated by Habib’s study [44]
shows that heart failure is the main symptom of LVNC. 43%
of patients with LVNC presented with heart failure and left
ventricular ejection fraction was lower than 30% in 46% of
patients. Other symptoms leading to diagnosis of LVNC were
arrhythmias (22%), familial screening (8%) and embolization
(4%). During the average 2.3-year follow up, advanced heart
failure developed in 31% of cases, in 8% cardiac transplanta-
tion was performed, in 7% malignant ventricular arrhythmias
were documented and in 28% of cases, cardioverter-
defibrillator was implanted (ICD). Atrial fibrillation was docu-
mented in 7% of cases and in 5% ischemic stroke occurred.
Pharmacologic treatment of heart failure in LVNC follows the
general rules for chronic heart failure [46]. In group of patients
with LVNC, favorable effect of cardiac resynchronization ther-
apy has been reported and the rate of adequate ICD interven-
tions after implantation for primary prevention was 33% during
40-month follow-up. Therefore, in patients with LVNC and
severe left ventricular systolic dysfunction, early ICD implanta-
tion is recommended [47]. Defibrillation threshold testing
should be performed on efficient anticoagulation therapy or
should not be performed at all due to high risk of thromboem-
bolic event. In severe heart failure, mechanical circulatory
support device implantation or heart transplantation should
be considered. Therapy of supraventricular and ventricular
arrhythmias follows the same rules as arrhythmias by other
structural affections of the heart. Anticoagulation therapy is
recommended for patients with LVNC and history of systemic
embolization, atrial fibrillation or ejection fraction lower than
40%. For the rest of the patients, acetylsalicylic acid is recom-
mended as thromboembolic prevention [3,42]. Careful clinical
screening in closest relatives of LVNC patients is important, as
it can reveal individuals with the same diagnosis or different
cardiomyopathy.
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In years to come, efforts to improve diagnostics of LVNC
thanks to more exact quantification of non-compact cardio-
myopathy are expected. The progress in genetic analysis
could contribute to better diagnostics and possibly to prog-
nostic stratification and screening of LVNC in families. It is
important to ensure systematic clinical screening in families
of patients with LVNC and early treatment of newly diag-
nosed individuals.
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